Patients with moderate to severe motor problems should use ExablateNeuro for pallidotomy.
FREMONT, CA: Minimally invasive ultrasonic wave pulses have been shown to improve the quality of life for Parkinsons disease patients by reducing tremors promptly and dramatically. Patients with severe Parkinson's disease who have mobility, rigidity, or dyskinesia symptoms can now receive treatment from Insightec®. This healthcare firm is developing the next generation of patient care by utilizing the therapeutic power of acoustic energy.
It is possible with the ExablateNeuro to accurately ablate the GPi during a pallidotomy by using concentrated ultrasonic pulses. Unlike invasive surgery, this treatment does not necessitate brain implants, and there is less chance of infection than with a scalpel.
For the treatment of medication-resistant Essential Tremor and Tremor-dominant Parkinsons Disease, the FDA approved the ExablateNeuro device in 2016. Patients with medication-resistant Essential Tremor and Tremor-dominant Parkinsons Disease are now being treated with the InsightecExablateNeuro device at 37 medical centers in the United States.
“Movement disorder neurologists now can offer their Parkinsons patients a less invasive surgical option as part of their treatment plan,” states Paul S. Fishman, MD, Ph.D., professor of neurology, pharmacology, and neurobiology at the University of Maryland School of Medicine.
“This approval is significant in that it adds Focused Ultrasound as an incisionless surgical option to treat motor symptoms of Parkinsons disease,” adds Howard M. Eisenberg, MD, R.K. Thompson Professor, Department of Neurosurgery at the University of Maryland and Principal Investigator.